Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 28:10:218.
doi: 10.1186/s13014-015-0528-z.

Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT)

Basel Altoos  1 , Arya Amini  1 , Muthanna Yacoub  2 , Maria T Bourlon  3 , Elizabeth E Kessler  4 , Thomas W Flaig  4 , Christine M Fisher  1 , Brian D Kavanagh  1 , Elaine T Lam  4 , Sana D Karam  5
Affiliations

Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT)

Basel Altoos et al. Radiat Oncol. .

Abstract

Background and purpose: We report the radiographic response rate of SBRT compared to conventional fractionated radiotherapy (CF-EBRT) for thoracic, abdominal, skin and soft tissue RCC lesions treated at our institution.

Material and methods: Fifty three lesions where included in the study (36 SBRT, 17 CF-EBRT), treated from 2004 to 2014 at our institution. We included patients that had thoracic, skin & soft tissue (SST), and abdominal metastases of histologically confirmed RCC. The most common SBRT fractionation was 50 Gy in 5 fractions.

Results: The median time of follow-up was 16 months (range 3-97 months). Median BED was 216.67 (range 66.67-460.0) for SBRT, and 60 (range 46.67-100.83) for CF-EBRT. Median radiographic local control rates at 12, 24, and 36 months were 100, 93.41, and 93.41 % for lesions treated with SBRT versus 62.02, 35.27 and 35.27 % for those treated with CF-EBRT (p < 0.001). Predictive factors for radiographic local control under univariate analysis included BED ≥ 100 Gy (HR, 0.048; 95 % CI, 0.006-0.382; p = 0.005), dose per fraction ≥ 9 Gy (HR, 0.631; 95 % CI, 0.429-0.931; p = 0.021), and gender (HR, 0.254; 95 % CI, 0.066-0.978; p = 0.048). Under multivariate analysis, there were no significant predictors for local control. Toxicity rates were low and equivalent in both groups, with no grade 4 or 5 side effects reported.

Conclusions: SBRT is safe and effective for the treatment of RCC metastases to thoracic, abdominal and integumentary soft tissues. Radiographic response rates were greater and more durable using SBRT compared to CF-EBRT. Further prospective trials are needed to evaluate efficacy and safety of SBRT for RCC metastases.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan-Meier curve demonstrating actuarial radiographic control rates between SBRT and CF-EBRT
Fig. 2
Fig. 2
Kaplan-Meier curve demonstrating Overall Survival Rates between SBRT and CF-EBRT
See this image and copyright information in PMC

References

    1. Amini A, Altoos B, Bourlon MT, Bedrick E, Bhatia S, Kessler ER, et al. Local control rates of metastatic renal cell carcinoma (rcc) to the bone using stereotactic body radiation therapy: Is rcc truly radioresistant? Practical radiation oncology 2015. doi:10.1016/j.prro.2015.05.004 - PMC - PubMed
    1. Chen FH, Chiang CS, Wang CC, Tsai CS, Jung SM, Lee CC, et al. Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in tramp-c1 prostate tumors. Clin Cancer Res. 2009;15:1721–9. - PMC - PubMed
    1. De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014;15:e170–7. doi: 10.1016/S1470-2045(13)70569-2. - DOI - PubMed
    1. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szcylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet. 2007;370:2103–11. doi: 10.1016/S0140-6736(07)61904-7. - DOI - PubMed
    1. Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii49–56. doi: 10.1093/annonc/mdu259. - DOI - PubMed

Publication types

MeSH terms